Skip to main content

Advertisement

SpringerLink
Log in

Target-mediated drug disposition model and its approximations for antibody–drug conjugates

  • Original Paper
  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

Abstract

Antibody–drug conjugate (ADC) is a complex structure composed of an antibody linked to several molecules of a biologically active cytotoxic drug. The number of ADC compounds in clinical development now exceeds 30, with two of them already on the market. However, there is no rigorous mechanistic model that describes pharmacokinetic (PK) properties of these compounds. PK modeling of ADCs is even more complicated than that of other biologics as the model should describe distribution, binding, and elimination of antibodies with different toxin load, and also the deconjugation process and PK of the released toxin. This work extends the target-mediated drug disposition (TMDD) model to describe ADCs, derives the rapid binding (quasi-equilibrium), quasi-steady-state, and Michaelis–Menten approximations of the TMDD model as applied to ADCs, derives the TMDD model and its approximations for ADCs with load-independent properties, and discusses further simplifications of the system under various assumptions. The developed models are shown to describe data simulated from the available clinical population PK models of trastuzumab emtansine (T-DM1), one of the two currently approved ADCs. Identifiability of model parameters is also discussed and illustrated on the simulated T-DM1 examples.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Mullard Asher (2013) Maturing antibody–drug conjugate pipeline hits 30. Nat Rev Drug Discovery 12:329–332

    Article  CAS  Google Scholar 

  2. Lin Tibbitts (2012) Pharmacokinetic considerations for antibody drug conjugates. Pharm Res 29:2353–2366

    Article  Google Scholar 

  3. Leipold D, Bender B, Xu K, Theil F-P, and Tibbitts J (2009) Understanding the de-conjugation of Trastuzumab-MCC-DM1 through application of a multi-compartmental model of individual drug: antibody species in cynomolgus monkey. Presented at the 2009 American Association for Cancer Research (AACR) Meeting, Denver, Colorado

  4. Bender B, Leipold D, Liu L, Xu K, Shen B-Q, Friberg LE, Tibbitts J. A multicompartmental population PK model elucidating the complex disposition of trastuzumab emtansine (T-DM1): an antibody-drug conjugate for the treatment of HER2-positive cancer, Page 21 (2012) Abstr 2607 [www.page-meeting.org/?abstract=2607]

  5. Lu D, Joshi A, Wang B, Olsen S, Yi JH, Krop IE, Burris HA, Sandhya Girish S, An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. Clin Pharmacokinet 52(8):657-672

  6. Chudasama VL, Schaedeli Stark F, Harrold JM, Tibbitts L, Girish SR, Gupta M, Frey N, Mager DE (2012) Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther 92(4):520–527. doi:10.1038/clpt.2012.153

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507–532

    Article  CAS  PubMed  Google Scholar 

  8. Mager DE, Krzyzanski W (2005) Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 22(10):1589–1596

    Article  CAS  PubMed  Google Scholar 

  9. Gibiansky L, Gibiansky E, Kakkar T, Ma P (2008) Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35(5):573–591

    Article  CAS  PubMed  Google Scholar 

  10. Gibiansky L, Gibiansky E (2009) Target-mediated drug disposition model: approximations, identifiability of model parameters, and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics. Expert Opin Drug Metabol Toxicol 5(7):803–812

    Article  CAS  Google Scholar 

  11. Yan X, Mager DE, Krzyzanski W (2010) Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn 37(1):25–47

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. QuantPharm LLC, North Potomac, MD, USA

    Leonid Gibiansky & Ekaterina Gibiansky

Authors
  1. Leonid Gibiansky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ekaterina Gibiansky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leonid Gibiansky.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 29 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gibiansky, L., Gibiansky, E. Target-mediated drug disposition model and its approximations for antibody–drug conjugates. J Pharmacokinet Pharmacodyn 41, 35–47 (2014). https://doi.org/10.1007/s10928-013-9344-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10928-013-9344-y

Keywords

Search

Navigation